// App-Quantinova.ai

3769 : Continuous, low intensity systemic dosing maximizes the therapeutic margin of Eg5/KSP inhibition in an orthotopic model of urothelial cell carcinoma

Researchers

Presenter

  • Leigh Williams

Principal Investigators

  • Rebecca Ellston

  • Dawn Trueman

  • Helen Musgrove

  • Linette Ruston

  • Brian Aquila

  • Elizabeth Pease

  • Stephanie Klein

  • Barry R. Davies

Medical Centers

  • AstraZeneca, Macclesfield, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Bladder Cancer

  • Thrombocytopenia

  • Fetal hydronephrosis

  • Neutropenia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved